Jasper Therapeutics (JSPR) is presenting data from the 180mg cohort of the Company’s SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab in adult participants with CIndU at the European Academy of Allergy and Clinical Immunology, EAACI, Annual Congress. Briquilimab administration resulted in deep disease control at 180mg, with 12 of 12 participants enrolled in the cohort achieving a clinical response within the 8-week preliminary analysis period. The efficacy observed was rapid and durable, with 8 of 12 participants achieving clinical response by week 2, and 7 of 12 participants maintaining clinical response through week 8. Briquilimab continued to be well tolerated in the study, with no serious adverse events and no grade 3 or higher adverse events reported in the 180mg cohort.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JSPR:
- Buy Rating for Jasper Therapeutics: Potential Breakthrough with Briquilimab in CSU Market
- Jasper Therapeutics price target lowered to $65 from $80 at Oppenheimer
- Jasper Therapeutics price target lowered to $33 from $38 at UBS
- Promising Advancements in Jasper Therapeutics’ Briquilimab Programs Highlight Market Potential
- Positive Outlook for Jasper Therapeutics: Promising Clinical Developments and Strategic Updates Support Buy Rating